A research team in Beijing has cracked a long‑standing mystery about why rapid‑acting antidepressants like ketamine and electroconvulsive therapy (ECT) work so quickly. By tracing the signal chain back to a tiny molecule called adenosine, the scientists proved that this “upstream” messenger is essential for the mood‑lifting effects of both drugs and a new non‑drug technique. Armed with this insight, the team engineered fresh ketamine‑like compounds that match or beat the original drug’s antidepressant power at lower doses and with far fewer side effects in animal tests. At the same time, they discovered that a safe, controlled breathing exercise—called acute intermittent hypoxia, which briefly mixes low‑oxygen air (about 9% O₂) with normal air—also spikes brain adenosine and produces a rapid lift in mood. The breakthrough, published in *Nature*, bridges the gap between theory and real‑world treatment, paving the way for safer pills and a simple breathing protocol that could help patients who haven’t responded to existing medicines. With clinical trials on the horizon, this discovery promises a new era of depression care that targets the root neurobiology rather than just masking symptoms.
Read moreA breakthrough was announced at the American Association for the Study of Liver Diseases meeting in Washington when Shanghai Heper Pharmaceuticals unveiled Phase II results for its experimental hepatitis B drug, Hepalatide. The double‑blind study showed that the medicine, which blocks the virus from entering liver cells, could reverse resistance to interferon therapy in patients who test positive for the three major hepatitis B markers. Even more striking, a subset of participants cleared the virus’s stubborn cccDNA, achieving what experts call a “sterilising cure” – the highest benchmark for hepatitis B treatment worldwide. The news arrives as China accelerates its push for homegrown innovative medicines, with new insurance schemes that blend public and commercial coverage to speed hospital access to cutting‑edge therapies. While Hepalatide’s success marks a major step forward, officials stress that broader reforms—such as improving diagnostic pathways for sleep disorders and streamlining administrative inspections—are also underway to support a healthier, more efficient medical system. The combined effort signals a hopeful future for patients battling chronic hepatitis B and underscores China’s growing role in global drug innovation.
Read moreThe 8th China International Import Expo (CIIE) kicked off in Shanghai on November 5, turning the city into a showcase for the latest medical‑device breakthroughs. With artificial intelligence now a core driver of innovation, multinational manufacturers used the event to highlight how AI is reshaping diagnosis and treatment for the nation’s biggest health challenges – heart disease and cancer. Siemens Healthineers stole the spotlight with a record‑size, 1,000‑square‑metre booth. Their new DSA angiography system delivers sub‑millimeter resolution in just 2.5 seconds and blends several AI tools from Chinese partners to guide neuro, cardiac and tumor interventions with unprecedented precision. Medtronic unveiled an FDA‑approved ultra‑rigid guidewire, the first of its kind, designed to boost the safety and predictability of transcatheter aortic valve replacement (TAVR) procedures. The company says the device will soon enter the Chinese market, offering doctors a more stable platform for heart‑valve implants. German endoscope leader Karl Storz introduced a second wave of domestically‑certified products, including cold‑light sources and pneumoperitoneum machines, and set up simulated outpatient cystoscopy and hysteroscopy suites to demonstrate how minimally invasive tools can enable same‑day surgeries and free up hospital resources. All of these launches dovetail with China’s aggressive “AI+” strategy, which aims to embed intelligent technologies across the medical sector. By accelerating AI‑driven R&D and local production, the expo signals a rapid shift of global medical‑device R&D toward China, promising faster access to cutting‑edge, AI‑enhanced care for Chinese patients.
Read more